Metastatic Colorectal Cancer
Conditions
Keywords
FOLFIRI, aflibercept, 5-FU, oxaliplatin, elderly, metastatic colorectal cancer
Brief summary
The purpose of this study is to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen
Interventions
DRUGAflibercept
4 mg/kg administered intravenous infusion on day 1
DRUGIrinotecan
180 mg/m2 intravenous infusion
DRUGfolinic acid (dl racemic)
400 mg/m2 intravenous infusion
DRUG5Fluorouracil
400 mg/m2 intravenous bolus
DRUG5-FU
2400 mg/m2 continuous intravenous infusion over 46 hours
Sponsors
Sanofi
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed and dated informed consent, and willing and able to comply with protocol requirements, 2. Histologically proven adenocarcinoma of the colon and/or rectum, 3. Existence of at least one measurable unidimensional lesion using CT or MRI based on the RECIST criteria, version 1.1 4. Patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after a first line oxaliplatin-containing regimen for metastatic disease. 5. Age ≥70 years 6. World Health Organization (WHO) Performance status (PS) 0-2, 7. Hematological status: neutrophils (ANC) ≥1.5x109 /L; platelets ≥100x109 /L; haemoglobin ≥9 g/dL 8. Adequate renal function: Creatinine clearance ≥50 mL/min as calculated using the Cockcroft-Gault equation. 9. Adequate liver function: serum bilirubin ≤1.5 x upper normal limit (ULN), alkaline phosphatase (ALP) \<5xULN 10. Proteinuria \<2+ (dipstick urinalysis) or ≤1g/24hour. 11. Regular follow-up feasible. 12. Male patients with a partner of childbearing potential must agree to use contraception in addition to having their partner use another contraceptive method during the trial.
Exclusion criteria
1. Uncontrolled hypercalcemia, 2. Pre-existing permanent neuropathy (NCI grade \>2) 3. Uncontrolled hypertension (defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy, 4. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy), 5. Treatment with any other investigational medicinal product within 28 days prior to study entry. 6. Other serious and uncontrolled non-malignant disease, 7. History or evidence upon physical examination of CNS metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy), 8. Patients classified as fragile or delicate according to the following criteria: 1. Dependence in one or more activities of daily living according to the Katz Index of Independence in Activities of Daily Living (ADL) scale 2. Three or more comorbidities when assessing the presence of the following processes: congestive heart failure; heart valve disease; coronary artery disease; chronic (obstructive or restrictive) pulmonary disease; cerebrovascular disease; peripheral neuropathy, chronic kidney failure; hypertension; diabetes; concomitant cancers; collagen vascular disease; chronic liver disease; and disabling arthritis 3. Presence of geriatric syndromes: moderate-severe dementia; delirium in stressful situations (urinary or respiratory tract infection, angina or drugs); moderate-severe depression that interferes with the patient's usual activity; frequent falls (three or more per month); inattentiveness (who could help you in the event of an emergency?); urinary incontinence in the absence of stress, infection, diuretics or prostatic hyperplasia; faecal incontinence in the absence of diarrhoea or laxatives; osteoporotic fractures of large bones or vertebral compression fractures 9. Known Gilbert's syndrome 10. Intolerance to atropine sulfate or loperamide 11. Known dihydropyrimidine dehydrogenase deficiency 12. Treatment with CYP3A4 inducers unless discontinued \> 7 days prior to inclusion 13. Any of the following in 3 months prior to inclusion: grade 3-4 gastrointestinal bleeding (unless due to resected tumor), treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or diverticulitis. 14. Other concomitant or previous malignancy, except: i/ adequately treated insitu carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for \>5 years, 15. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days 16. Patients with known allergy to any excipient to study drugs, 17. History of myocardial infarction and/or stroke within 6 months prior to inclusion, NYHA class III and IV congestive heart failure 18. Bowel obstruction. 19. Less than 28 days elapsed from prior radiotherapy 20. Patients with pernicious anemia or other megaloblastic anemias due to vitamin B12 deficiency 21. Patients with severe infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | 48 months |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate based on the RECIST criteria | 48 months |
| Disease control rate | 48 months |
| Depth of response | 48 months |
| Time to progression | 48 months |
| Overall survival | 48 months |
| Incidence and severity of AEs CTCAE v4.03 criteria | 48 months |
| Incidence of dose adjustments and compliance | 48 months |
| VES-13 score (Vulnerable Elders Survey) as the utility measure for health deterioration | 48 months |
| Time to treatment failure | 48 months |
Other
| Measure | Time frame |
|---|---|
| Biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with efficacy parameters | 48 months |
Countries
Spain
Outcome results
None listed